Stock Comparison
ABT vs DXCM
Abbott Laboratories and DexCom Inc side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$163.94B
$27.07B
P/E (TTM)
26.4
30.1
Forward P/E
17.2
26.8
Price/Sales
3.6
5.6
Price/Book
3.2
9.0
EV/EBITDA
16.1
17.2
Dividend Yield
2.62%
—
Profitability
Net Margin
13.90%
19.30%
Operating Margin
13.50%
21.40%
Return on Equity
12.30%
35.60%
Return on Assets
5.59%
9.65%
Growth (YoY)
Revenue Growth
7.80%
15.00%
Earnings Growth
-19.70%
92.20%
Price & Risk
Beta
0.6
1.4
52-Week High
$135.34
$89.98
52-Week Low
$81.97
$54.11
Analyst Target
$116.54
$85.24
Compare ABT and DXCM your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.